Skip to main content

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

News

Dr. Nathanial Moorman delivers the November 2023 FDA CERSI Lecture on READDI

Published

Research Triangle CERSI
Thursday, November 9, 2023

About the Presentation

In an era where the threat of pandemics looms large, READDI emerges as a beacon of hope and innovation. This presentation delved into the groundbreaking efforts of READDI, a leading non-profit drug company dedicated to developing small molecule antiviral drugs aimed at combating the viruses responsible for global pandemics. In this talk, we explored the cutting-edge research and development initiatives undertaken by READDI to create effective antiviral solutions. Focused exclusively on small molecules, these groundbreaking drugs represent a new frontier in the battle against viral outbreaks. This presentation provided a comprehensive overview of READDI’s innovative methodologies, from computational drug design and high-throughput screening to preclinical studies and clinical trials. Attendees gained insights into the potential impact of READDI, Inc.’s antiviral drugs on global public health. By targeting the viruses responsible for pandemics, these advancements have the potential to save lives, minimize economic disruptions, and bolster healthcare infrastructures worldwide. We also discussed the challenges faced in the process, emphasizing the importance of international collaboration and preparedness in the face of emerging viral threats.

About the Presenter

Dr. Nathaniel Moorman is READDI co-founder, scientific adviser, and associate professor in the UNC School of Medicine’s microbiology and immunology department. His research focuses on developing broad spectrum antiviral drugs that work against entire families of viruses that cause outbreaks, epidemics and pandemics. Dr. Moorman uses a combination of new technologies and traditional molecular virology techniques to investigate host-pathogen interactions. He leads multiple ongoing efforts to discover and develop novel direct-acting and host-targeted antiviral drugs for viruses of pandemic concern.

Dr. Moorman received a Bachelor of Science in microbiology from the University of Illinois Urbana-Champaign and his PhD from Washington University at St. Louis. He completed his postdoctoral training at Princeton University prior to joining the faculty at the University of North Carolina at Chapel Hill in 2010.

News originally published by the FDA

FDA Regulatory Science News and Events

Visit the FDA CERSI website for news and events related to the Advancing Regulatory Science Initiative.